Genetic make-up of the total AML cohort. (A) Frequency of recurrent mutations. Proportion of patients based on the number of karyotypic aberrations (B) and frequency of recurring cytogenetic abnormalities (C). The assignment of patients to particular cytogenetic subgroups was not hierarchical; therefore, a single patient could be assigned to multiple subgroups when appropriate (ie, when >1 cytogenetic aberration was found).